Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study

NCT02366026 is registered in ClinicalTrials.gov with Immune Response BioPharma, Inc. as lead sponsor.

NCT NCT02366026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02366026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study
Lead sponsor
Immune Response BioPharma, Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
June 30, 2017
Completion date
June 30, 2019
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv